Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6699MR)

This product GTTS-WQ6699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5306MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ7626MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ15856MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ15602MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ8488MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ6171MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ12956MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW